US regulators have approved a combination of Bristol-Myers Squibb’s immunotherapy drugs Opdivo and Yervoy as a first-line treatment for patients with advanced renal cell carcinoma.
Original Article: BMS’ Opdivo/Yervoy combo cleared for kidney cancer